Intervention

Aluminum hydroxide

ClinicalTrials.gov intervention label

Clinical trials10

Recruiting0

Common conditions3

Lead sponsors shown3

Clinical trials

10 shown

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset SubjectsNCT00529399 · 2009-02-01

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy AdultsNCT00001052

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative SubjectsNCT00001053

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.NCT00001044

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3NCT00000779

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected IndividualsNCT00001042

Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected WomenNCT00000809

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative VolunteersNCT00000868

The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in MonkeysNCT00031109

A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible VaccinesNCT00002402

Common conditions

HIV Infections9 HIV Seronegativity2 Type 1 Diabetes Mellitus1

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID)8 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1 VaxGen1

Trial status mix

COMPLETED9

WITHDRAWN1

Phase mix

PHASE18

NA1

PHASE21

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.